Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...